Sickle Cell Transition – General concepts about sickle cell disease: Adopting NHLBI guidelines

Presented by:
Ofelia Alvarez, MD
Professor of Clinical Pediatrics & Director, Pediatric Sickle Cell Program
Department of Pediatrics, University of Miami

Faculty Disclosure: Ofelia Alvarez, MD has disclosed that she was a consultant for Forma Therapeutics and Global Blood Therapeutics in the last 24 months. The relationships have since ended. No one else in a position to control content has any financial relationships to disclose. Conflict of interest information for the CME Advisory Committee members can be found on the following website: All relevant financial relationships have been mitigated.

Release Date: November 1, 2021
Expiration Date: October 31, 2022

Target Audience: Primary Care Physicians, Specialty Physicians, Physician Assistants, Nurses, Pharmacists

Learning Objectives:
As a result of participation in this activity, participants should be able to:

  • Discuss the NHLBI sickle cell guidelines and other updated guidelines proposed by the American Society of Hematology (with emphasis on recommendations for adults and adolescents with SCD) including pain management.
  • Review the use of hydroxyurea and other newer medications in the management of SCD.
  • Learn what resources are available to help with the care of sickle cell patients.

Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.

Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resource(s) for further study:

  •  Expert panel report, Evidence-based management of sickle cell disease, 2014 (electronic version)
  • Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014; 312 (10): 1033-1048 (paper summary version)
  • Brandow AM, Carroll CP, Creary S, et al.  American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020 Jun 23: 4(12): 2656-2701.
  • Liem RI, Lanzkron S, Coates T, et al.  American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.  Blood Adv. 2019 Dec 10; 3(23): 3867-3897.



For additional information, contact Debbie Ringdahl at 352-273-9120 or e-mail